"Everybody wants to be successful," Ray Cohen said in an interview. "But the question I ask people is, 'Are you prepared to ...

Medical device giant Boston Scientific announced a $3.7 billion deal on Monday to augment its urology portfolio. The company is acquiring Axonics, a maker of neurostimulation devices that treat ...

I am retired from being a CEO and don’t plan on starting a newco—I am focused on board service and helping companies access ...

A California jury ruled on Wednesday that Axonics did not infringe three of Medtronic’s patents related to sacral neuromodulation. The latest decision resolves a lawsuit that has been ongoing since ...

Axonics has secured $40 million to support commercialization of its neuromodulatory treatment of urinary and bowel dysfunction. The financing comes as Axonics closes in on the end of a clinical trial ...

Hot on the heels of the U.S. launch of its recharge-free neurostimulation implant to treat incontinence, Axonics is bringing yet another of its sacral neuromodulation (SNM) devices to our neighbors to ...

Axonics Modulation Technologies Inc. Chief Executive Ray Cohen is nothing if not confident about becoming the market leader in his urology device category, despite renewed competition from medtech ...

Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion. It’s the first billion-dollar medical device deal of 2024 ...

Shares jump after the medical device maker announces that it has secured an important regulatory win. The FDA granted premarket approval for the Axonics r-SNM System as a treatment for urinary urge ...

Medtronic is upping the ante in a patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic’s InterStim device, an implanted ...